Evidence map›Paper›PMID 41805900›Full record

ArticlePLoS computational biology2026

Multi-ACPNet: A multi-scale sequence-structure feature fusion framework for anticancer peptide identification and functional prediction.

Lu Meng, Lijun Zhou

Abstract read
In one paragraph

Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lu MengCollege of Information Science and Engineering, Northeastern University, Shenyang, China.ORCID https://orcid.org/0000-0003-2442-8354
Lijun ZhouCollege of Information Science and Engineering, Northeastern University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anticancer peptides (ACPs) have emerged as promising therapeutic candidates for cancer treatment due to their high efficacy and low propensity for inducing drug resistance. However, existing ACP identification methods primarily rely on peptide sequence features while neglecting spatial structural characteristics. Moreover, few approaches can simultaneously predict the functional activity of ACPs. To address these limitations, this study proposes Multi-ACPNet, a novel dual-function predictor capable of both ACP identification and activity type classification. This model innovatively integrates sequence and structural features through a multi-stage framework. It employs a hybrid Bidirectional Long Short-Term Memory (BiLSTM) and causal convolutional network to capture both long-range dependencies and local sequence patterns, followed by a multi-scale Graph Convolutional Network (GCN) that dynamically fuses local and long-range structural dependencies using residual connections and adaptive weighting. Experimental results demonstrate that Multi-ACPNet achieves outstanding performance, with Accuracy of 0.8140, 0.9536, and 0.8770 on three benchmark datasets for ACP identification. For functional prediction, it attains an AUC of 0.9033, F1-score of 0.8472, and Hamming loss of 0.1303, significantly outperforming state-of-the-art predictors.

Indexed as

Antineoplastic AgentsComputational BiologyPeptidesAlgorithmsAmino Acid SequenceDatabases, ProteinGraph Neural NetworksHumansLong Short Term MemoryPrediction AlgorithmsSequence Analysis, ProteinAntineoplastic AgentsPeptides

Identifiers

PMID41805900
PMCPMC12987591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.